1 | 11C-ACETATE | 2件: Acetate Acetate, Acetic acid C-11 | - | - | - | 4件: 6 6, 13, 86, 88 |
2 | [18F]Fluoro-2-deoxy-2-D-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: D00009
D00009
| - | - | 2件: 86 86, 88 |
3 | Acetate | 1件: Acetate Acetate | - | - | - | 41件: 1 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 171, 206, 222, 224, 225, 227, 235, 251, 265, 288, 298, 299 |
4 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 |
5 | ACT-293987 | - | - | - | - | 3件: 51 51, 86, 88 |
6 | Adempas | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 5件: 51 51, 86, 88, 225, 299 |
7 | Adempas (Riociguat, BAY63-2521) | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
8 | Adempas® | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
9 | Ambrisentan | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 7件: 51 51, 84, 85, 86, 88, 210, 211 |
10 | Ambrisentan 5 mg | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
11 | Atorvastatin | 1件: Atorvastatin Atorvastatin | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 19件: 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 |
12 | BARNASCAN | - | - | - | - | 1件: 88 88 |
13 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 |
14 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
15 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
16 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
17 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
18 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
19 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 |
20 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 |
21 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 |
22 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 |
23 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 |
24 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 |
25 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 |
26 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 |
27 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 |
28 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
29 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
30 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
31 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
32 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
33 | BAY1237592 | - | - | - | - | 2件: 86 86, 88 |
34 | Blood sample | - | - | - | - | 20件: 8 8, 13, 46, 49, 51, 53, 61, 66, 84, 88, 96, 97, 107, 127, 235, 274, 280, 288, 294, 299 |
35 | Bosentan | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
36 | BOSENTAN MONOHYDRATE | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 84, 86, 88 |
37 | BPA | - | - | - | - | 1件: 88 88 |
38 | Cysteine | 1件: Cysteine Cysteine | - | - | - | 10件: 13 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 |
39 | D-glucose | 1件: D-glucose D-glucose | 1件: D00009
D00009
| - | - | 3件: 49 49, 86, 88 |
40 | Dapagliflozin | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 7件: 19 19, 49, 66, 67, 86, 88, 222 |
41 | Dapagliflozin 10 MG [Farxiga] | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
42 | Edoxaban | 1件: Edoxaban Edoxaban | 1件: D09710
D09710
| 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 2件: 46 46, 88 |
43 | Fludeoxyglucose | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: D01843
D01843
| - | - | 3件: 84 84, 85, 88 |
44 | Forxiga | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
45 | Forxiga (dapagliflozin) | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
46 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 12件: 2 2, 6, 13, 49, 50, 66, 86, 88, 96, 97, 257, 299 |
47 | GSK1325760 | - | - | - | - | 2件: 86 86, 88 |
48 | Imatinib | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
49 | IMATINIB MESILATE | 1件: Imatinib Imatinib | 1件: D08066
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 3件: 13 13, 86, 88 |
50 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
51 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
52 | Macitentan | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 5件: 51 51, 85, 86, 88, 210 |
53 | Macitentan 10 mg | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 |
54 | Macitentan 10mg | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 88 |
55 | MACITENTAN COMPRESSE | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
56 | MACITENTAN TABLETS | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
57 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 |
58 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 |
59 | MK-4836 | - | - | - | - | 2件: 86 86, 88 |
60 | MultiHance | 1件: Gadobenic acid Gadobenic acid | 1件: D08018
D08018
| - | - | 2件: 86 86, 88 |
61 | N-acetyl cysteine | 1件: Cysteine Cysteine | - | - | - | 6件: 13 13, 34, 85, 88, 296, 310 |
62 | NITRIC OXIDE | 1件: Nitric Oxide Nitric Oxide | 1件: D00074
D00074
| - | - | 7件: 85 85, 86, 88, 210, 251, 294, 299 |
63 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 |
64 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 |
65 | Opsumit | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
66 | Opsumit® | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
67 | Oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 13件: 6 6, 49, 70, 85, 86, 88, 90, 96, 168, 193, 271, 299, 330 |
68 | Oxygen, liquid | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 2件: 86 86, 88 |
69 | Placebo | - | - | - | - | 28件: 3 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
70 | Potassium | 1件: Potassium Potassium | 1件: D08403
D08403
| - | - | 13件: 36 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235 |
71 | Remodulin | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 86 86, 88 |
72 | Remodulin (R) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 |
73 | Remodulin 10mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 |
74 | Remodulin 1mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 |
75 | Remodulin 2.5mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 |
76 | Remodulin 5mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 |
77 | RIOCIGUAT | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 6件: 51 51, 84, 86, 88, 225, 299 |
78 | Riociguat (Adempas, BAY63-2521) | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 86, 88, 299 |
79 | Riociguat Oral Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 |
80 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 |
81 | Sauerstoff | - | - | - | - | 2件: 86 86, 88 |
82 | SELEXIPAG | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 5件: 51 51, 70, 84, 86, 88 |
83 | Systemic anticoagulation | - | - | - | - | 1件: 88 88 |
84 | Tracleer | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 13 13, 51, 84, 85, 86, 88, 210, 211 |
85 | TRACLEER 125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
86 | TRACLEER*56CPR RIV 125MG | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 |
87 | Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 6件: 51 51, 84, 85, 86, 88, 210 |
88 | TREPROSTINIL SODIUM | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 3件: 51 51, 86, 88 |
89 | Uptravi | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 3件: 84 84, 86, 88 |
90 | Volibris | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 85, 86, 88 |
91 | Warfarin | 1件: Warfarin Warfarin | 1件: D08682
D08682
| 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 11件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91 |
92 | Warfarin Potassium | 2件: Potassium Potassium, Warfarin | 2件: D08403
D08403
,
D08682
| 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 88 88 |